SOURCE FACT
Pfizer states that it licensed the program from Spark Therapeutics in 2014 and assumed pivotal studies, regulatory activities, and potential global commercialization.
Loading relationship source…FORMAT SAMPLE · NOT A CURRENT GENERATED REPORT
Reviewable diligence brief
This page demonstrates the report structure with a limited public-source example. It is not customer data, a recommendation, or a claim of comprehensive coverage.
1
Entity Passport
2
Claim-level evidence
AI INTERPRETATION
The licensing history should be considered separately from trial sponsorship and current ticker-issuer identity.
Interpretation only; inspect the linked relationship source before relying on it.